Alterity Therapeutics Ltd

자세한 내용은 Alterity Therapeutics Ltd 회사

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

회사 정보

종목 코드 ATHE

회사 이름Alterity Therapeutics Ltd

상장일Mar 28, 2000

CEODr. David A. Stamler, M.D.

직원 수10

유형Depository Receipt

회계 연도 종료Mar 28

주소L 3 460 Bourke St

도시MELBOURNE

증권 거래소NASDAQ Capital Market Consolidated

국가Australia

우편 번호3000

전화61393494906

웹사이트https://alteritytherapeutics.com/

종목 코드 ATHE

상장일Mar 28, 2000

CEODr. David A. Stamler, M.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Ms. Abby Macnish Niven

Chief Financial Officer, Company Secretary

--

Mr. Lawrence B. Gozlan

Non-Executive Director

--

Mr. Peter Ashley Marks

Non-Executive Independent Director

--

Mr. Brian Derek Meltzer

Non-Executive Independent Director

--

Ms. Hannah Howlett

Investor Relations

--

Mr. Geoffrey Paul Kempler

Non-Executive Chairman of the Board

--

Dr. David A. Stamler, M.D.

Chief Executive Officer

--

이름

이름/직위

직위

주식 보유

변동

Ms. Abby Macnish Niven

Chief Financial Officer, Company Secretary

--

Mr. Lawrence B. Gozlan

Non-Executive Director

--

Mr. Peter Ashley Marks

Non-Executive Independent Director

--

Mr. Brian Derek Meltzer

Non-Executive Independent Director

--

Ms. Hannah Howlett

Investor Relations

--

Mr. Geoffrey Paul Kempler

Non-Executive Chairman of the Board

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sun, Jul 20

주주

주주 유형

주주

비율

Point72 Asset Management, L.P.

0.86%

Morgan Stanley & Co. LLC

0.28%

Greenleaf Trust

0.11%

UBS Financial Services, Inc.

0.08%

BNP Paribas Securities Corp. North America

0.06%

Other

98.60%

주주

비율

Point72 Asset Management, L.P.

0.86%

Morgan Stanley & Co. LLC

0.28%

Greenleaf Trust

0.11%

UBS Financial Services, Inc.

0.08%

BNP Paribas Securities Corp. North America

0.06%

Other

98.60%

주주 유형

주주

비율

Hedge Fund

0.86%

Research Firm

0.35%

Bank and Trust

0.11%

Investment Advisor

0.09%

Private Equity

0.04%

Other

98.56%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

25

222.41K

1.45%

+22.59K

2025Q1

25

242.89K

1.60%

+14.64K

2024Q4

25

125.35K

1.13%

-75.38K

2024Q3

25

113.89K

1.28%

-62.37K

2024Q2

24

79.19K

0.91%

-96.76K

2024Q1

24

95.17K

1.09%

-51.08K

2023Q4

23

88.25K

1.89%

-31.21K

2023Q3

26

59.08K

1.45%

-63.37K

2023Q2

27

58.44K

1.44%

-90.15K

2023Q1

26

93.79K

2.31%

-17.38K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Point72 Asset Management, L.P.

131.43K

0.86%

+98.80K

+302.83%

Mar 31, 2025

Morgan Stanley & Co. LLC

43.63K

0.29%

-700.00

-1.58%

Mar 31, 2025

UBS Financial Services, Inc.

13.00K

0.09%

+12.62K

+3286.46%

Mar 31, 2025

BNP Paribas Securities Corp. North America

9.75K

0.06%

+962.00

+10.94%

Mar 31, 2025

Twin Lakes Capital

5.92K

0.04%

--

Mar 31, 2025

Geode Capital Management, L.L.C.

1.16K

0.01%

--

May 31, 2025

Osaic Holdings, Inc.

181.00

0%

--

Mar 31, 2025

Rhumbline Advisers Ltd. Partnership

130.00

0%

+130.00

--

Mar 31, 2025

55IP

53.00

0%

+53.00

--

Mar 31, 2025

5.210USD

Alterity Therapeutics Ltd

5.210

개요

회사

금융